Squarepoint
KPTI icon

Squarepoint’s Karyopharm Therapeutics KPTI Stock Holding History

Squarepoint’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$623K Buy
+63,801
New +$553K ﹤0.01% 3252
2025
Q1 		– Sell
-1,386
Closed -$14.1K – 5038
2024
Q4 		$14.1K Buy
+1,386
New +$16.8K ﹤0.01% 4951
2023
Q4 		– Sell
-2,277
Closed -$45.8K – 4260
2023
Q3 		$45.8K Buy
+2,277
New +$51.1K ﹤0.01% 3645
2023
Q2 		– Sell
-837
Closed -$48.8K – 3800
2023
Q1 		$48.8K Sell
837
-2,649
-76% -$131K ﹤0.01% 3065
2022
Q4 		$178K Buy
+3,486
New +$242K ﹤0.01% 2826
2022
Q1 		– Sell
-8,285
Closed -$799K – 3204
2021
Q4 		$799K Buy
+8,285
New +$826K ﹤0.01% 1839
2021
Q3 		– Sell
-2,294
Closed -$355K – 3183
2021
Q2 		$355K Buy
+2,294
New +$333K ﹤0.01% 2402
2021
Q1 		– Sell
-5,337
Closed -$1.24M – 3370
2020
Q4 		$1.24M Sell
5,337
-5,231
-49% -$1.21M 0.01% 1188
2020
Q3 		$2.31M Buy
10,568
+7,811
+283% +$1.91M 0.03% 595
2020
Q2 		$783K Sell
2,757
-1,059
-28% -$313K 0.01% 1075
2020
Q1 		$1.1M Buy
3,816
+2,257
+145% +$623K 0.03% 685
2019
Q4 		$448K Buy
+1,559
New +$338K ﹤0.01% 1833
2019
Q3 		– Sell
-1,304
Closed -$117K – 2521
2019
Q2 		$117K Buy
+1,304
New +$105K ﹤0.01% 2203
2019
Q1 		– Sell
-3,521
Closed -$495K – 2300
2018
Q4 		$495K Buy
3,521
+48
+1% +$8.1K 0.01% 1248
2018
Q3 		$887K Buy
3,473
+2,493
+254% +$689K 0.01% 1046
2018
Q2 		$250K Buy
+980
New +$242K ﹤0.01% 1458
2018
Q1 		– Sell
-860
Closed -$124K – 1928
2017
Q4 		$124K Buy
+860
New +$138K ﹤0.01% 1915
2017
Q1 		– Sell
-1,140
Closed -$161K – 1724
2016
Q4 		$161K Buy
+1,140
New +$154K 0.01% 1515

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's KPTI Position: Q2 2026 in Review

Squarepoint opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 63,801 shares worth $623K. The stake represents ﹤0.01% of the portfolio and ranks #3252 among its holdings. This is a return to the name: Squarepoint previously reported a position in KPTI as recently as Q4 2024.

Squarepoint first reported a position in KPTI in Q4 2016 and has held it in 18 quarters since. The position peaked at $2.31M in Q3 2020. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Squarepoint held 63,801 shares of Karyopharm Therapeutics worth $623K as of Q2 2026.
  • Karyopharm Therapeutics was a new Squarepoint position in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3252 holding.
  • Squarepoint first reported a position in Karyopharm Therapeutics in Q4 2016 and has held it in 18 quarters since.
  • Squarepoint's Karyopharm Therapeutics position peaked at $2.31M in Q3 2020.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.